Recommended PEP regimens

2-drug regimens^:

Tenofovir disoproxil fumarate 300mg with lamivudine 300mg (Daily)*
OR
Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg (Daily)

3-drug regimens:

Your preferred 2-drug regimen PLUS
dolutegravir 50mg (Daily)
OR
raltegravir 400mg (BD)
OR
rilpivirine 25mg (Daily)

^ Zidovudine, in combination with lamivudine, can be used in two-drug PEP combinations. The benefits of cheaper zidovudine cost are offset by the need for a twice-daily treatment regimen, higher incidences of gastrointestinal side effects, myalgia and headaches in comparison to the recommended regimens.
* TGA-approved generic lamivudine may be used to reduce cost.

Dolutegravir, raltegravir or rilpivirine as the 3rd drug:

The current guidelines recommend dolutegravir or raltegravir or rilpivirine as the 3rd drug in PEP. Using three drugs for PEP increases the likelihood of an adverse event e.g. drug-drug interactions and the potential for rhabdomyolysis with raltegravir. See Table 7 for further details.

See Appendix 1: for the comparative cost of different PEP regimens.

Print